Skip to main content

Advertisement

ADVERTISEMENT

News

AmnioWrap2 - BioStem Technologies

https://clinicaltrials.gov/study/NCT06511596

BioStem Technologies initiated a 60-patient RCT to evaluate the safety and efficacy of AmnioWrap2 plus SoC vs SoC only for treatment of DFUs with primary outcome of % of wound closure over 12 weeks. Not yet recruiting; estimated study completion is Dec 2025.clinicaltrials.gov

Advertisement

Advertisement

Advertisement